Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, Rainer Strotmann, Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, Rainer Strotmann
Abstract
Purpose: Tepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy and safety outcomes.
Methods: Exposure-efficacy analyses included data from an ongoing phase 2 study (VISION) investigating 500 mg/day tepotinib in NSCLC harboring METex14 skipping alterations. Efficacy endpoints included objective response, duration of response, and progression-free survival. Exposure-safety analyses included data from VISION, plus four completed studies in advanced solid tumors/hepatocellular carcinoma (30-1400 mg). Safety endpoints included edema, serum albumin, creatinine, amylase, lipase, alanine aminotransferase, aspartate aminotransferase, and QT interval corrected using Fridericia's method (QTcF).
Results: Tepotinib exhibited flat exposure-efficacy relationships for all endpoints within the exposure range observed with 500 mg/day. Tepotinib also exhibited flat exposure-safety relationships for all endpoints within the exposure range observed with 30-1400 mg doses. Edema is the most frequently reported adverse event and the most frequent cause of tepotinib dose reductions and interruptions; however, the effect plateaued at low exposures. Concentration-QTc analyses using data from 30 to 1400 mg tepotinib resulted in the upper bounds of the 90% confidence interval being less than 10 ms for the mean exposures at the therapeutic (500 mg) and supratherapeutic (1000 mg) doses.
Conclusions: These analyses provide important quantitative pharmacologic support for benefit/risk assessment of the 500 mg/day dosage of tepotinib as being appropriate for the treatment of NSCLC harboring METex14 skipping alterations.
Registration numbers: NCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.
Keywords: Dose selection; METex14 skipping alteration; NSCLC; Targeted therapies; Tyrosine kinase inhibitor.
Conflict of interest statement
Wenyuan Xiong was employed by Merck Healthcare KGaA, Darmstadt, Germany for the duration of the study. Sofia Friberg Hietala and Joachim Nyberg are employees of Pharmetheus AB, Sweden. Orestis Papasouliotis, Andreas Johne, Karin Berghoff, Kosalaram Goteti, Jennifer Dong, Pascal Girard, Karthik Venkatakrishnan, and Rainer Strotmann are employees of Merck Healthcare KGaA, Darmstadt, Germany.
© 2022. The Author(s).
Figures
References
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 6, 2022. To view the most recent and complete version of the guideline, go online to . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39:1040–1091. doi: 10.1200/JCO.20.03570.
- Salgia R, Sattler M, Scheele J, et al. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020;87:102022. doi: 10.1016/j.ctrv.2020.102022.
- Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850–859. doi: 10.1158/-15-0285.
- Cortot AB, Kherrouche Z, Descarpentries C, et al. Exon 14 deleted MET receptor as a new biomarker and target in cancers. J Natl Cancer Inst. 2017;109:djq262. doi: 10.1093/jnci/djw262.
- Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383:931–943. doi: 10.1056/NEJMoa2004407.
- Bladt F, Friese-Hamim M, Ihling C, et al. The c-Met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models. Cancers (Basel) 2014;6:1736–1752. doi: 10.3390/cancers6031736.
- Friese-Hamim M, Bladt F, Locatelli G, et al. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Am J Cancer Res. 2017;7:962–972.
- Wu ZX, Teng QX, Cai CY, et al. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochem Pharmacol. 2019;166:120–127. doi: 10.1016/J.BCP.2019.05.015.
- Bladt F, Faden B, Friese-Hamim M, et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res. 2013;19:2941–2951. doi: 10.1158/1078-0432.ccr-12-3247.
- Falchook GS, Kurzrock R, Amin HM, et al. First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res. 2020;26:1237–1246. doi: 10.1158/1078-0432.CCR-19-2860.
- Shitara K, Yamazaki K, Tsushima T, et al. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. Jpn J Clin Oncol. 2020;50:859–866. doi: 10.1093/jjco/hyaa042.
- Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132–1143. doi: 10.1016/S2213-2600(20)30154-5.
- Xiong W, Papasouliotis O, Jonsson EN. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study. Cancer Chemother Pharmacol. 2022;89:655–669. doi: 10.1007/s00280-022-04423-5.
- Mazieres J, Paik PK, Felip E, et al (2020) 1283P—Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: overall efficacy results from VISION cohort A. Ann Oncol 31: Poster 1283P. 10.1016/j.annonc.2020.08.1597
- Gastonguay MR (2011) Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. Presented at: PAGE, Athens, Greece
- Decaens T, Barone C, Assenat E, et al. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer. 2021;125:190–199. doi: 10.1038/s41416-021-01334-9.
- Ryoo B-Y, Cheng A-L, Ren Z, et al. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer. 2021;125:200–208. doi: 10.1038/S41416-021-01380-3.
- Johne A, Scheible H, Becker A, et al. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs. 2020;38:1507–1519. doi: 10.1007/s10637-020-00926-1.
- National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. . Accessed 21 Oct 2021
- Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15:1463–1468. doi: 10.1023/A:1011970125687.
- Jonsson EN, Harling K (2018) Increasing the efficiency of the covariate search algorithm in the SCM. Presented at: PAGE, Athens, Greece
- Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2017;45:383–397. doi: 10.1007/S10928-017-9558-5.
- Veillon R, Sakai H, Le X, et al (2020) FP14.09 – Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: updated results from the VISION trial. J Thorac Oncol 16: FP14.09. 10.1016/j.jtho.2021.01.152
- Venkatakrishnan K, Friberg L, Ouellet D, et al. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther. 2015;97:37–54. doi: 10.1002/CPT.7.
- Bullock JM, Lin T, Bilic S. Clinical pharmacology tools and evaluations to facilitate comprehensive dose finding in oncology: a continuous risk-benefit approach. J Clin Pharmacol. 2017;57:S105–S115. doi: 10.1002/JCPH.908.
- Bullock JM, Rahman A, Liu Q. Lessons learned: dose selection of small molecule-targeted oncology drugs. Clin Cancer Res. 2016;22:2630–2638. doi: 10.1158/1078-0432.CCR-15-2646.
- Faucette S, Wagh S, Trivedi A, et al. Reverse translation of US Food and Drug Administration reviews of oncology new molecular entities approved in 2011–2017: lessons learned for anticancer drug development. Clin Transl Sci. 2018;11:123–146. doi: 10.1111/CTS.12527.
- Parchment RE, Doroshow JH. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Semin Oncol. 2016;43:514–525. doi: 10.1053/J.SEMINONCOL.2016.07.002.
- Venkatakrishnan K, Ecsedy J. Enhancing value of clinical pharmacodynamics in oncology drug development: an alliance between quantitative pharmacology and translational science. Clin Pharmacol Ther. 2017;101:99–113. doi: 10.1002/CPT.544.
- Blanc-Durand F, Alameddine R, Iafrate AJ, et al. Tepotinib efficacy in a patient with non-small cell lung cancer with brain metastasis harboring an HLA-DRB1-MET gene fusion. Oncologist. 2020;25:916–920. doi: 10.1634/theoncologist.2020-0502.
- Paik P, Sakai H, Felip E, et al. MA11.05 – Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: updated efficacy results from VISION cohort A. J Thorac Oncol. 2021;16:174. doi: 10.1016/j.jtho.2021.01.250.
- Tong JH, Yeung SF, Chan AWH, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22:3048–3056. doi: 10.1158/1078-0432.CCR-15-2061.
- Wolf J, Seto T, Han J-YY, et al. Capmatinib in MET exon 14–mutated or MET -amplified non–small-cell lung cancer. N Engl J Med. 2020;383:944–957. doi: 10.1056/nejmoa2002787.
- Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1247–1255. doi: 10.1001/JAMAONCOL.2020.2218.
- Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 2018;211:57–65. doi: 10.1007/978-3-319-91442-8_4.
- Usatyuk PV, Fu P, Mohan V, et al. Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells *. J Biol Chem. 2014;289:13476–13491. doi: 10.1074/JBC.M113.527556.
- Yamada N, Nakagawa S, Horai S, et al. Hepatocyte growth factor enhances the barrier function in primary cultures of rat brain microvascular endothelial cells. Microvasc Res. 2014;92:41–49. doi: 10.1016/J.MVR.2013.12.004.
- Morley R, Cardenas A, Hawkins P, et al. Safety of onartuzumab in patients with solid tumors: experience to date from the onartuzumab clinical trial program. PLoS One. 2015;10:e0139679. doi: 10.1371/JOURNAL.PONE.0139679.
- Tabernero J, Elez ME, Herranz M, et al. A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin Cancer Res. 2014;20:2793–2804. doi: 10.1158/1078-0432.CCR-13-1837.
- Mathialagan S, Rodrigues AD, Feng B. Evaluation of renal transporter inhibition using creatinine as a substrate in vitro to assess the clinical risk of elevated serum creatinine. J Pharm Sci. 2017;106:2535–2541. doi: 10.1016/J.XPHS.2017.04.009.
- Mohan A, Herrmann S. Capmatinib-induced pseudo-acute kidney injury: a case report. Am J Kidney Dis. 2021 doi: 10.1053/J.AJKD.2021.04.009.
- Topletz-Erickson AR, Lee AJ, Mayor JG, et al. Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects. J Clin Pharmacol. 2021;61:461–471. doi: 10.1002/JCPH.1750.
- Scotcher D, Arya V, Yang X, et al. A novel physiologically based model of creatinine renal disposition to integrate current knowledge of systems parameters and clinical observations. CPT Pharmacomet Syst Pharmacol. 2020;9:310–321. doi: 10.1002/PSP4.12509.
Source: PubMed